Wells Fargo Maintains Equal-Weight on bluebird bio, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Equal-Weight rating on bluebird bio (NASDAQ:BLUE) but has reduced the price target from $8 to $5.
December 15, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Yanan Zhu maintains an Equal-Weight rating on bluebird bio but lowers the price target from $8 to $5, indicating a potential downside in the stock's value.
The reduction in the price target for bluebird bio by a major financial institution like Wells Fargo suggests that the analyst sees less potential for the stock's growth or a higher risk profile, which could lead to a negative investor sentiment and a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100